CXCL8 Specific Neutra™ Antibody Products
Product listAre you facing challenges in neutralizing CXCL8-mediated pathological signaling or struggling with inconsistent results in inflammation and cancer studies? Creative Biolabs' CXCL8 specific Neutra™ antibody products overcome these hurdles through advanced epitope-specific engineering, enabling robust blockade of CXCL8-receptor interactions to deliver reproducible, high-impact data.
Introduction to CXCL8
CXCL8 (C-X-C motif chemokine ligand 8), also known as interleukin-8 (IL-8), is a prototypic pro-inflammatory chemokine central to neutrophil recruitment and activation. Secreted by macrophages, endothelial cells, and tumor cells, CXCL8 orchestrates immune responses in acute and chronic inflammation while driving tumor progression and metastasis.
- Basic Information
CXCL8 is a 72-amino-acid protein encoded by the CXCL8 gene, constitutively expressed at low levels but dramatically upregulated during infection, tissue injury, or hypoxia. Its synthesis is tightly regulated by NF-κB and AP-1 transcription factors, with elevated levels observed in inflammatory diseases, autoimmune disorders, and multiple cancers.
- Structural Insights
The mature CXCL8 protein adopts a conserved chemokine fold stabilized by two disulfide bonds. Monomeric CXCL8 binds heparan sulfate proteoglycans to form tissue-specific concentration gradients. Functional activity depends on dimerization, mediated by interactions between the N-loop and β1-strand domains, enabling high-affinity engagement with its receptors, CXCR1 and CXCR2.
- Signaling Pathways
CXCL8 activates G protein-coupled receptors CXCR1/2, triggering downstream pathways including MAPK, PI3K/Akt, and JAK/STAT. This cascade enhances neutrophil chemotaxis, degranulation, and ROS production. In cancer, CXCL8 signaling promotes angiogenesis, epithelial-mesenchymal transition (EMT), and immunosuppressive microenvironment formation via recruitment of myeloid-derived suppressor cells (MDSCs).
Fig.1 CXCL8-mediated neutrophil attraction to and activation at the inflammatory site.1
- Disease Relevance
CXCL8 overexpression is implicated in chronic obstructive pulmonary disease (COPD), rheumatoid arthritis, psoriasis, and inflammatory bowel disease (IBD). In oncology, it drives tumor growth, metastasis, and therapy resistance in breast, lung, and colorectal cancers by fostering immunosuppression and stromal remodeling.
Applications of CXCL8 Neutralizing Antibodies
- Therapeutic Development for Chronic Inflammation
Anti-CXCL8 antibodies reduce neutrophil infiltration and cytokine storms in preclinical models of acute respiratory distress syndrome (ARDS) and sepsis. Clinical trials highlight their potential to mitigate steroid-resistant inflammation in severe asthma and COPD.
- Oncology Immunotherapy
By blocking CXCL8-induced immunosuppression, these antibodies enhance T-cell infiltration and synergize with checkpoint inhibitors. In pancreatic cancer models, CXCL8 neutralization delays metastasis and improves chemotherapy response rates.
- Targeting Tumor Microenvironment
CXCL8-neutralizing agents inhibit angiogenesis by suppressing VEGF expression in endothelial cells. They also reverse EMT, sensitizing resistant tumors to EGFR/HER2-targeted therapies.
- Biomarker-Driven Diagnostics
Quantifying CXCL8 levels in serum or biopsies using validated antibodies aids in stratifying patients for anti-inflammatory or anti-angiogenic therapies, enabling personalized treatment regimens.
Neutralizing Antibodies Targeting CXCL8
Creative Biolabs' anti-CXCL8 neutralizing antibodies are engineered to disrupt CXCL8 dimerization or receptor binding, validated for specificity across ELISA, flow cytometry, and in vivo models. These antibodies exhibit:
- High affinity (KD < 1 nM) for both monomeric and dimeric CXCL8.
- Cross-reactivity with primate and rodent homologs for translational studies.
- Functional efficacy in blocking neutrophil migration and tumor angiogenesis.
Creative Biolabs' CXCL8 specific Neutra™ antibody products empower researchers to dissect complex inflammatory and oncogenic pathways with precision. Our antibodies are rigorously optimized for specificity, reproducibility, and in vivo performance. Contact our team today to explore custom solutions for your CXCL8-focused projects and accelerate your therapeutic breakthroughs.
REFERENCE
- Cambier, Seppe, Mieke Gouwy, and Paul Proost. "The chemokines CXCL8 and CXCL12: molecular and functional properties, role in disease and efforts towards pharmacological intervention." Cellular & molecular immunology 20.3 (2023): 217-251. Distributed under Open Access license CC BY 4.0, without modification. https://doi.org/10.1038/s41423-023-00974-6
